Jubilant Life Sciences is currently trading at Rs. 173.20, up by 6.05 points or 3.62% from its previous closing of Rs. 167.15 on the BSE.
The scrip opened at Rs. 168.00 and has touched a high and low of Rs. 180.10 and Rs. 163.40 respectively. So far 162884 shares were traded on the counter.
The BSE group 'A' stock of face value Re. 1 has touched a 52 week high of Rs. 222.00 on 13-Jun-2014 and a 52 week low of Rs. 116.10 on 17-Dec-2014.
Last one week high and low of the scrip stood at Rs. 188.45 and Rs. 156.45 respectively. The current market cap of the company is Rs. 2738.04 crore.
The promoters holding in the company stood at 54.02% while Institutions and Non-Institutions held 22.47% and 23.50% respectively.
Jubilant Life Sciences, an integrated Pharmaceuticals and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Montelukast Sodium Chewable Tablets, 4 mg and 5 mg, the generic version of Singulair Chewable Tablets (of Merck), which is used for the treatment of asthma and to relieve symptoms of seasonal allergies. The total market size for Montelukast Tablets as per IMS is $83 Million per annum.
Jubilant Life Sciences had a total of 781 filings for formulations of which 333 have been approved in various regions globally, as on December 31, 2014. This includes 72 ANDAs filed in the US, of which 35 have been approved and 46 Dossier filings in Europe. The company has so far received 10 ANDA approvals during FY 2015.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: